(MENAFN- GetNews) (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Fuchs Dystrophy pipeline constitutes 5+ key companies continuously working towards developing 5+ Fuchs ...
Design Therapeutics is set to present significant safety findings from its Phase 1 trial of DT-168, highlighting progress in their clinical development for treating Fuchs endothelial corneal dystrophy ...
CARLSBAD, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today ...
NEW ORLEANS — Rho kinase inhibitor eyedrops stimulate the growth of corneal epithelium, according to a preliminary study in patients with Fuchs dystrophy. "Think outside the box," said Shigeru ...
Design Therapeutics Inc. has described transcription modulators reported to be useful for the treatment of myotonic dystrophy type 1 (DM1) and Fuchs’ dystrophy.
Important insights into the mechanisms behind Fuchs endothelial corneal dystrophy (FECD), a common cause of age-related visual loss, have been revealed in a new study led by UCL researchers. A new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results